Successful Transport of Blood Samples with Small Drones
|
By LabMedica International staff writers Posted on 17 Aug 2015 |

Image: Preparation of clinical blood samples for test-flights by small drone. (1) Left: Custom-cut foam block. (2) Right: Placement of sealed foam lock in the bio-hazard bags as well as absorbent material for potential sample containment (Photos courtesy of Johns Hopkins Medicine and PLOS One).

Image: (3) Left: Placement of first bio-hazard bag inside the second bio-hazard bag. (4) Middle-right: Placement of double-wrapped payload in the fuselage (Photo courtesy of Johns Hopkins Medicine and PLOS One).

Image: (5) Left: Covered, secured, and labeled fuselage. (6) Right: Launch with hand toss (Photo courtesy of Johns Hopkins Medicine and PLOS One).
A proof-of-concept, initial study has shown that small unmanned aerial systems (UAS) could potentially be used to transport clinical blood specimens for diagnostics without damage to the specimens.
In a first rigorous examination published about the impact of drone transport on biological samples, a team of clinical researchers and engineers, led by Timothy Kien Amukele, MD, PhD, pathologist at Johns Hopkins University School of Medicine (Baltimore, MD, USA) and director of a collaboration with Makerere University in Uganda, found that results of common, routine tests on the blood samples were not affected by up to 40 minutes of sample-travel in hobby-sized drones. This could especially aid millions of people in developing nations where most tests are currently done by dedicated laboratories that can be scores of miles from remote clinics in rural and economically impoverished areas that lack, for example, good roads.
“Biological samples can be very sensitive and fragile,” said Dr. Amukele. That sensitivity makes even the pneumatic-tube systems used by many hospitals, for example, unsuitable for transporting blood for certain purposes. Of particular concern related to sample transport in drones is the sudden acceleration that marks the launch of the vehicle and the jostling when the drone lands on its belly. “Such movements could have destroyed blood cells or prompted blood to coagulate and I thought all kinds of blood tests might be affected, but our study shows they weren’t,” he added.
For the study, total of 6 blood samples were collected from each of 56 healthy adult volunteers at Johns Hopkins Hospital. Samples were driven to a flight site an hour’s drive from the hospital on days when the temperature was moderate. There, half the samples were held stationary (non-flight); the other half were packaged for protection during the in-flight environment and to prevent leakage, then loaded into a hand-launched fixed-wing drone and flown for periods of 6–38 minutes. Owing to Federal Aviation Administration (FAA) rules, the flights were conducted in an unpopulated area, kept below 100 meters and in the line-of-sight of the certified drone pilot.
Samples were driven back from the flight-field to the Johns Hopkins Hospital Core Laboratory, where 33 of the most common chemistry, hematology, and coagulation tests were performed (tests that together account for around 80% of all such tests performed), including for sodium, glucose, and red blood cell count.
Comparing lab results of the flown vs. non-flown samples from each volunteer showed that these flights essentially had no impact, although the precision of one blood test—for total carbon dioxide (the bicarbonate test)—did differ for some samples pairs. This may be because the blood sat for up to 8 hours before being tested, but whether the out-of-range results were due to this time lag or to the drone transport is unknown. Nevertheless, there were no consistent differences in results between the flown vs. non-flown blood.
“The ideal way to test that would be to fly the blood around immediately after drawing it, but neither the FAA nor Johns Hopkins would like drones flying around the hospital,” said Dr. Amukele.
The likely next step is a pilot study in Africa where clinics are sometimes 60 or more miles away from labs. “A drone could go 100 km in 40 minutes,” said Dr. Amukele, “They’re less expensive than motorcycles, are not subject to traffic delays, and the technology already exists for the drone to be programmed to “home” to certain GPS coordinates, like a carrier pigeon.”
Drones have already been tested as carriers of medicines to clinics in remote areas, but whether and how drones will be used to carry medicines and potentially infectious patient specimens over more populated areas will depend on laws and regulations.
The study, by Amukele TK, et al, was published July 29, 2015, in the journal PLOS One.
Related Links:
Johns Hopkins University School of Medicine
In a first rigorous examination published about the impact of drone transport on biological samples, a team of clinical researchers and engineers, led by Timothy Kien Amukele, MD, PhD, pathologist at Johns Hopkins University School of Medicine (Baltimore, MD, USA) and director of a collaboration with Makerere University in Uganda, found that results of common, routine tests on the blood samples were not affected by up to 40 minutes of sample-travel in hobby-sized drones. This could especially aid millions of people in developing nations where most tests are currently done by dedicated laboratories that can be scores of miles from remote clinics in rural and economically impoverished areas that lack, for example, good roads.
“Biological samples can be very sensitive and fragile,” said Dr. Amukele. That sensitivity makes even the pneumatic-tube systems used by many hospitals, for example, unsuitable for transporting blood for certain purposes. Of particular concern related to sample transport in drones is the sudden acceleration that marks the launch of the vehicle and the jostling when the drone lands on its belly. “Such movements could have destroyed blood cells or prompted blood to coagulate and I thought all kinds of blood tests might be affected, but our study shows they weren’t,” he added.
For the study, total of 6 blood samples were collected from each of 56 healthy adult volunteers at Johns Hopkins Hospital. Samples were driven to a flight site an hour’s drive from the hospital on days when the temperature was moderate. There, half the samples were held stationary (non-flight); the other half were packaged for protection during the in-flight environment and to prevent leakage, then loaded into a hand-launched fixed-wing drone and flown for periods of 6–38 minutes. Owing to Federal Aviation Administration (FAA) rules, the flights were conducted in an unpopulated area, kept below 100 meters and in the line-of-sight of the certified drone pilot.
Samples were driven back from the flight-field to the Johns Hopkins Hospital Core Laboratory, where 33 of the most common chemistry, hematology, and coagulation tests were performed (tests that together account for around 80% of all such tests performed), including for sodium, glucose, and red blood cell count.
Comparing lab results of the flown vs. non-flown samples from each volunteer showed that these flights essentially had no impact, although the precision of one blood test—for total carbon dioxide (the bicarbonate test)—did differ for some samples pairs. This may be because the blood sat for up to 8 hours before being tested, but whether the out-of-range results were due to this time lag or to the drone transport is unknown. Nevertheless, there were no consistent differences in results between the flown vs. non-flown blood.
“The ideal way to test that would be to fly the blood around immediately after drawing it, but neither the FAA nor Johns Hopkins would like drones flying around the hospital,” said Dr. Amukele.
The likely next step is a pilot study in Africa where clinics are sometimes 60 or more miles away from labs. “A drone could go 100 km in 40 minutes,” said Dr. Amukele, “They’re less expensive than motorcycles, are not subject to traffic delays, and the technology already exists for the drone to be programmed to “home” to certain GPS coordinates, like a carrier pigeon.”
Drones have already been tested as carriers of medicines to clinics in remote areas, but whether and how drones will be used to carry medicines and potentially infectious patient specimens over more populated areas will depend on laws and regulations.
The study, by Amukele TK, et al, was published July 29, 2015, in the journal PLOS One.
Related Links:
Johns Hopkins University School of Medicine
Latest Hematology News
- New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
- Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
- Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Channels
Clinical Chemistry
view channel
Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more
Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read moreMolecular Diagnostics
view channel
Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more
Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read moreMicrobiology
view channel
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read moreProteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read morePathology
view channel
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more




 Assay.jpg)


